Pharmaceutical intermediates
Abrocitinib Intermediates
4 pharmaceutical intermediates for Abrocitinib. Indication: Atopic Dermatitis.
About Abrocitinib
- Originator
- Pfizer Inc
- Indication
- Atopic Dermatitis
- Approved Date
- 01/14/2022
- NCE Patent
- 01/14/2027
- DS/DP
- 02/19/2031
Available intermediates
4 intermediates currently listed for Abrocitinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| benzyl ((1s,3s)-3-(methylamino)cyclobutyl)carbamate | 1353501-22-0 | / | / |
| Carbamic acid, N-[cis-3-(methylamino)cyclobutyl]-, phenylmethyl ester, hydrochloride (1:1) | 2204290-99-1 | / | / |
| 3-Oxocyclobutane-1-carboxylicacid | 23761-23-1 | / | / |
| Benzyl 3-oxocyclobutylcarbamate | 130369-36-7 | / | / |
Building toward Abrocitinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →